Clindamycin phosphate 1.2% and benzoyl peroxide 2.5%: A new, once-daily, Fixed combination treatment for moderate to severe acne

Cosmetic Dermatology

Volumn 22, Issue 6, 2009, Pages 319-322

  Cook Bolden, Fran ^a,b  

^a Skin Specialty Group   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053358414     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39(2 pt 3):S34-S37. (Pubitemid 28367284)
2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37. (Pubitemid 36791495)
3. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother. 1982;21:770-772. (Pubitemid 12006526)
4. Gupta AK, Lynde CW, Kunynetz RA, et al. A randomized, doubleblind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003;7:31-37. (Pubitemid 36350856)
5. Waller JM, Dreher F, Behnam S, et al. ' Keratolytic' properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol. 2006;19:283-289. (Pubitemid 44329095)
6. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, doubleblind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133. (Pubitemid 34833234)
7. Leyden J, Kaidbey SF, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. an in vivo comparative study. Am J Clin Dermatol. 2001;2:263-266.
8. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595. (Pubitemid 27446730)
9. Tucker R, Walton S. The role of benzoyl peroxide in the management of acne vulgaris. Pharm J. 2007;279:48-53. (Pubitemid 47162496)
10. Haustein UF, Tegetmeyer L, Ziegler V. Allergic and irritant potential of benzoyl peroxide. Contact Dermatitis. 1985;13:252-257. (Pubitemid 16217410)
11. Mills OH Jr, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664-667. (Pubitemid 17210594)
12. Serup J, Lindblad AK, Maroti M, et al. To follow or not to follow dermatological treatment-a review of the literature. Acta Derm Venereol. 2006;86:193-197. (Pubitemid 43875201)
13. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59:792-800.
14. Bucks D, Sarpotdar P, Yu K, et al. The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel with minimal irritation and enhanced bioavailability. J Drugs Dermatol. In press.
15. Bucks D, Yu K, Angel A, et al. Can delivery be enhanced and skin irritation minimized using a lower concentration of benzoyl peroxide in a fixed combination product? Poster presented at: 67th Annual Meeting of the American Academy of Dermatology; March 6, 2009; San Francisco, CA. P717.